News RA pill setback spoils Lilly’s growth story Eli Lilly has posted a strong 8% increase in sales for the second quarter, led by grow
News AbbVie looks beyond Humira as RA pill meets phase 3 targets Upadacitinib hopes drug will reduce reliance on Humira.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
